GRAIL, Inc. (GRAL) research
GRAIL, Inc.- Sector
- Biotechnology
- Last price
- $108.52
- As of
GRAIL, Inc. (GRAL): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-06.
As of . Source: SEC EDGAR filings for GRAL. Method and limitations.
Share the GRAL intelligence card
See GRAL live in the terminal
Track GRAL's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live GRAL terminal, freeActive signals for GRAL
- highCONSENSUS_SELL
3 tracked funds reduced GRAL this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 83% of GRAL (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +186% to GRAL (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 92% of GRAL (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +158% to GRAL (2026Q2)
FREE, NO ACCOUNT
Every signal on GRAL, as it fires
You are seeing 5 of 27 signals recorded on GRAL since 2026-05-30.
The five above landed across 2 days. The other 22 were recorded on 4 other days. 21 of the 27 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in GRAL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 384747101 · 2026Q2 | $7.9M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 384747101 · 2026Q2 | $1.9M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 384747101 · 2026Q2 | $628K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, GRAL
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
GRAL against its peers
GRAL's operating margin of -382.0% ranks in the 30th percentile of 14 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | GRAL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 147M USD | 241M USD | 44 | 16 |
| Operating margin | -382.0% | -61.5% | 30 | 14 |
| Net margin | -277.5% | -45.2% | 30 | 14 |
| Return on equity | -15.8% | -29.5% | 67 | 22 |
Peers (23): IDYA, LEGN, GRTX, VKTX, CPRX, DYN, ELVN, CELC, DNLI, TNGX, VCYT, RCUS, RLAY, CLDX, TLX, QURE, MBX, ARQT, MANE, IOVA, ZLAB, ACAD, EWTX. Left out: ZLDPF (no annual filing), PBLS (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (GRAL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more GRAL signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to GRALand get the insider, 13F, options, and confluence read in one view.